Drug Profile
P/DEA
Latest Information Update: 27 Jan 1995
Price :
$50
*
At a glance
- Originator Aventis
- Class
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 27 Jan 1995 No-Development-Reported for Mycobacterium avium complex infections in USA (Unknown route)